New drugs take too long to get to market because of clinical trial bottlenecks. Two cancer doctors built AI-enabled tech to speed up the process. https://t.co/XO01YCVQ41 https://t.co/XO01YCVQ41 ...

In the latest trading session, Abbott (ABT) closed at $132.02, marking a -1.18% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.33%. Meanwhile, the Dow experienced a drop of 0.63%, and the technology-dominated Nasdaq saw a decrease of 0.22%. Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had lost 2.09% lagged the Medical sector's loss of 0.32% and the S&P 500's gain of 4.07%.The investment community will be paying close ...

Join the club today. Go to CNBC. com.>> Our newsmaker this hour. Doctor Marty Makary the FDA commissioner marking his first 100 days on the job. It's been a busy few months with many changes at the agency from vaccines to staffing.Good morning doctor. >> Good morning Joe. I don't.>> Know, maybe you've been on a few times. I don't remember, but we all went through that, that period together, obviously. And there's a lot of look back now at, at that period.I was you know it's a hot button issue and sometimes ...

July 9, 2025 03:22 AM GMT China Healthcare | Asia Pacific M Update A Potential 200% US Tariff on Pharmaceuticals - How Feasible Is It? Key Takeaways Generic drugs: There is currently an acute shortage of sterile injectables in the US. A report from the US FDA earlier this year highlighted 102 generic medicines, 70% of which were injectables, that were under-supplied from 2019-2024. The biggest categories were anesthesia, endocrinology, gastroenterology, oncology, and cardiovascular injections (note). Generi ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Abbott (ABT) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on July 17, might help the stock move higher if these key numbers are better than expectations. On th ...

Industry Challenge - Clinical trial bottlenecks cause delays in new drug launches [1] AI Solution - AI-enabled technology aims to accelerate the clinical trial process [1] Company Focus - Two cancer doctors developed the AI solution [1]

We'll be announcing something very soon on pharmaceuticals. Uh we're going to give people about a year, a year and a half to come in and after that they're going to be tariffed. If they have to bring the pharmaceuticals into the country, the drugs and other things into the country, they're going to be tariffed at a very, very high rate, like 200%.We'll give them a certain period of time to get their act together. But they were all here. Now they all left.They went to other places because we allowed people t ...

Older patients taking GLP-1 drugs for diabetes face twice the risk of developing a serious eye disease, a new study says https://t.co/DHKsJVaF4m ...

And we'll be announcing something very soon on pharmaceuticals. We're going to give people about a year, a year and a half to come in. And after that, they're going to be tariffed. If they have to bring the pharmaceuticals into the country, the drugs and other things into the country, they're going to be tariffed at a very, very high rate, like 200%.We'll give them a certain period of time to get their act together. But they were all here. Now, they all left.They went to other places because we allowed peop ...

Core Insights - GSK plc is a prominent biopharmaceutical company focused on developing specialty and general drugs, as well as vaccines [1] Financial Performance - GSK's Q1 2025 results demonstrated strong momentum, particularly in the specialty medicines segment [1] - The oncology performance of GSK was noted as excellent, indicating a robust growth area for the company [1]